IBRO Neuroscience Reports最新文献

A multi-omics target study for glioblastoma multiforme (GBM) based on Mendelian randomization analysis

IF 2 Q3 NEUROSCIENCES

IBRO Neuroscience Reports

Pub Date : 2025-03-01 DOI: 10.1016/j.ibneur.2025.02.011

Hao Sun , Xiangyin Liu , Jiaze Lu , Hao Fan , Dongxiao Lu , Haohan Sun , Zijian Zhou , Yuming Li , Xianyong Yin , Yuwen Song , Shan Wang , Tao Xin

Background

Glioblastoma multiforme (GBM) is the most frequent type of primary malignant brain tumor. This study utilized Mendelian randomization (MR) analysis to explore the causal link between proteins in plasma and cerebrospinal fluid and GBM.

Aims

This study aimed to identify proteins in both plasma and cerebrospinal fluid (CSF) that could serve as potential therapeutic targets for GBM.

Methods

We employed previously published protein quantitative trait loci (pQTL) data from CSF and plasma as the exposure data, alongside aggregated Genome-Wide Association Study (GWAS) data on GBM for our MR analysis. Furthermore, we conducted Bayesian co-localization analysis and examined the protein-protein interaction (PPI) networks of CSF and plasma proteins related to GBM risk.

Results

MR identified three key proteins linked to GBM risk: ribophorin I (RPN1) in plasma, von Willebrand factor (vWF) and macrophage-stimulating protein (MSP). in CSF. Elevated RPN1 and MSP were associated with decreased GBM risk, while increased vWF was linked to higher risk. External validation confirmed that RPN1 served as a key protein in GBM development. Bayesian co-localization showed a 10.35 % probability of a shared causal variant between RPN1 and GBM. Protein-protein interaction analysis further highlighted related proteins for RPN1.

Conclusions

In summary, the plasma protein RPN1 and the CSF proteins vWF and MSP are causally associated with the risk of GBM. Further research is needed to clarify the roles of these candidate proteins in GBM. Notably, RPN1 may serve as a potential therapeutic target for GBM. Future clinical studies on GBM treatment could explore drugs targeting RPN1.

{"title":"A multi-omics target study for glioblastoma multiforme (GBM) based on Mendelian randomization analysis","authors":"Hao Sun , Xiangyin Liu , Jiaze Lu , Hao Fan , Dongxiao Lu , Haohan Sun , Zijian Zhou , Yuming Li , Xianyong Yin , Yuwen Song , Shan Wang , Tao Xin","doi":"10.1016/j.ibneur.2025.02.011","DOIUrl":"10.1016/j.ibneur.2025.02.011","url":null,"abstract":"<div><h3>Background</h3><div>Glioblastoma multiforme (GBM) is the most frequent type of primary malignant brain tumor. This study utilized Mendelian randomization (MR) analysis to explore the causal link between proteins in plasma and cerebrospinal fluid and GBM.</div></div><div><h3>Aims</h3><div>This study aimed to identify proteins in both plasma and cerebrospinal fluid (CSF) that could serve as potential therapeutic targets for GBM.</div></div><div><h3>Methods</h3><div>We employed previously published protein quantitative trait loci (pQTL) data from CSF and plasma as the exposure data, alongside aggregated Genome-Wide Association Study (GWAS) data on GBM for our MR analysis. Furthermore, we conducted Bayesian co-localization analysis and examined the protein-protein interaction (PPI) networks of CSF and plasma proteins related to GBM risk.</div></div><div><h3>Results</h3><div>MR identified three key proteins linked to GBM risk: ribophorin I (RPN1) in plasma, von Willebrand factor (vWF) and macrophage-stimulating protein (MSP). in CSF. Elevated RPN1 and MSP were associated with decreased GBM risk, while increased vWF was linked to higher risk. External validation confirmed that RPN1 served as a key protein in GBM development. Bayesian co-localization showed a 10.35 % probability of a shared causal variant between RPN1 and GBM. Protein-protein interaction analysis further highlighted related proteins for RPN1.</div></div><div><h3>Conclusions</h3><div>In summary, the plasma protein RPN1 and the CSF proteins vWF and MSP are causally associated with the risk of GBM. Further research is needed to clarify the roles of these candidate proteins in GBM. Notably, RPN1 may serve as a potential therapeutic target for GBM. Future clinical studies on GBM treatment could explore drugs targeting RPN1.</div></div>","PeriodicalId":13195,"journal":{"name":"IBRO Neuroscience Reports","volume":"18 ","pages":"Pages 400-408"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143550152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of intracerebroventricular administration of dimethyl sulfoxide on hippocampal electrophysiology in mice

IF 2 Q3 NEUROSCIENCES

IBRO Neuroscience Reports

Pub Date : 2025-02-27 DOI: 10.1016/j.ibneur.2025.02.016

Jeroen Spanoghe, Arne Van Acker, Evelien Carrette, Kristl Vonck, Paul Boon, Robrecht Raedt

Dimethyl sulfoxide (DMSO) is a commonly used solvent in life sciences due to its excellent ability to dissolve compounds with poor water-solubility. Depending on the applied dose, the variety of DMSO’s physiological and biological effects may compromise its suitability as a vehicle molecule. Even low concentrations of DMSO are known to affect neuronal excitability in vitro. As in vivo effects have not been studied extensively, this exploratory study investigated the effects of intracerebroventricular (ICV) administration of different DMSO concentrations on hippocampal electrophysiology in mice. Acute recordings of hippocampal evoked potentials (EPs) and electroencephalography (EEG) were performed before and after ICV injection of a 5 µl DMSO solution, with concentrations ranging from 2.5 % to 100 % DMSO. Solutions containing up to 50 % DMSO had no acute effects on hippocampal electrophysiology. Administration of 75 % and 100 % DMSO was found to alter evoked responses, indicating increased excitability. Our results indicate that DMSO can be used as a vehicle in volumes of 5 µl containing concentrations of up to 50 % without affecting acute hippocampal electrophysiological studies in mice. Higher concentrations should be avoided as these affect neuronal excitability.

{"title":"Effects of intracerebroventricular administration of dimethyl sulfoxide on hippocampal electrophysiology in mice","authors":"Jeroen Spanoghe, Arne Van Acker, Evelien Carrette, Kristl Vonck, Paul Boon, Robrecht Raedt","doi":"10.1016/j.ibneur.2025.02.016","DOIUrl":"10.1016/j.ibneur.2025.02.016","url":null,"abstract":"<div><div>Dimethyl sulfoxide (DMSO) is a commonly used solvent in life sciences due to its excellent ability to dissolve compounds with poor water-solubility. Depending on the applied dose, the variety of DMSO’s physiological and biological effects may compromise its suitability as a vehicle molecule. Even low concentrations of DMSO are known to affect neuronal excitability <em>in vitro</em>. As <em>in vivo</em> effects have not been studied extensively, this exploratory study investigated the effects of intracerebroventricular (ICV) administration of different DMSO concentrations on hippocampal electrophysiology in mice. Acute recordings of hippocampal evoked potentials (EPs) and electroencephalography (EEG) were performed before and after ICV injection of a 5 µl DMSO solution, with concentrations ranging from 2.5 % to 100 % DMSO. Solutions containing up to 50 % DMSO had no acute effects on hippocampal electrophysiology. Administration of 75 % and 100 % DMSO was found to alter evoked responses, indicating increased excitability. Our results indicate that DMSO can be used as a vehicle in volumes of 5 µl containing concentrations of up to 50 % without affecting acute hippocampal electrophysiological studies in mice. Higher concentrations should be avoided as these affect neuronal excitability.</div></div>","PeriodicalId":13195,"journal":{"name":"IBRO Neuroscience Reports","volume":"18 ","pages":"Pages 378-383"},"PeriodicalIF":2.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143520173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A systematic review of the pain-related emotional and cognitive impairments in chronic inflammatory pain induced by CFA injection and its mechanism

IF 2 Q3 NEUROSCIENCES

IBRO Neuroscience Reports

Pub Date : 2025-02-27 DOI: 10.1016/j.ibneur.2025.02.015

Naixuan Wei , Zi Guo , Ru Ye , Lu Guan , Junhui Ren , Yi Liang , Xiaomei Shao , Jianqiao Fang , Junfan Fang , Junying Du

Emotional and cognitive impairments are comorbidities commonly associated with chronic inflammatory pain. To summarize the rules and mechanisms of comorbidities in a complete Freund’s adjuvant (CFA)-induced pain model, we conducted a systematic review of 66 experimental studies identified in a search of three databases (PubMed, Web of Science, and ScienceDirect). Anxiety-like behaviors developed at 1- or 3-days post-CFA induction but also appeared between 2- and 4 weeks post-induction. Pain aversion, pain depression, and cognitive impairments were primarily observed within 2 weeks, 4 weeks, and 2–4 weeks post-CFA injection, respectively. The potential mechanisms underlying the comorbidities between pain and anxiety predominantly involved heightened neuronal excitability, enhanced excitatory synaptic transmission, and neuroinflammation of anterior cingulate cortex (ACC) and amygdala. The primary somatosensory cortex (S1)^Glu→caudal dorsolateral striatum (cDLS)^GABA, medial septum (MS)^CHAT→rACC, rACC^Glu→thalamus, parabrachial nucleus (PBN)→central nucleus amygdala (CeA), mediodorsal thalamus (MD)→basolateral amygdala (BLA), insular cortex (IC)→BLA and anteromedial thalamus nucleus (AM)^CaMKⅡ→midcingulate cortex (MCC)^CaMKⅡ pathways are enhanced in the pain-anxiety comorbidity. The ventral hippocampal CA1 (vCA1)→BLA and BLA→CeA pathways were decreased in the pain-anxiety comorbidity. The BLA→ACC pathway was enhanced in the pain-depression comorbidity. The infralimbic cortex (IL)→locus coeruleus (LC) pathway was enhanced whereas the vCA1→IL pathway was decreased, in the pain-cognition comorbidity. Inflammation/neuroinflammation, oxidative stress, apoptosis, ferroptosis, gut-brain axis dysfunction, and gut microbiota dysbiosis also contribute to these comorbidities.

{"title":"A systematic review of the pain-related emotional and cognitive impairments in chronic inflammatory pain induced by CFA injection and its mechanism","authors":"Naixuan Wei , Zi Guo , Ru Ye , Lu Guan , Junhui Ren , Yi Liang , Xiaomei Shao , Jianqiao Fang , Junfan Fang , Junying Du","doi":"10.1016/j.ibneur.2025.02.015","DOIUrl":"10.1016/j.ibneur.2025.02.015","url":null,"abstract":"<div><div>Emotional and cognitive impairments are comorbidities commonly associated with chronic inflammatory pain. To summarize the rules and mechanisms of comorbidities in a complete Freund’s adjuvant (CFA)-induced pain model, we conducted a systematic review of 66 experimental studies identified in a search of three databases (PubMed, Web of Science, and ScienceDirect). Anxiety-like behaviors developed at 1- or 3-days post-CFA induction but also appeared between 2- and 4 weeks post-induction. Pain aversion, pain depression, and cognitive impairments were primarily observed within 2 weeks, 4 weeks, and 2–4 weeks post-CFA injection, respectively. The potential mechanisms underlying the comorbidities between pain and anxiety predominantly involved heightened neuronal excitability, enhanced excitatory synaptic transmission, and neuroinflammation of anterior cingulate cortex (ACC) and amygdala. The primary somatosensory cortex (S1)<sup>Glu</sup>→caudal dorsolateral striatum (cDLS)<sup>GABA</sup>, medial septum (MS)<sup>CHAT</sup>→rACC, rACC<sup>Glu</sup>→thalamus, parabrachial nucleus (PBN)→central nucleus amygdala (CeA), mediodorsal thalamus (MD)→basolateral amygdala (BLA), insular cortex (IC)→BLA and anteromedial thalamus nucleus (AM)<sup>CaMKⅡ</sup>→midcingulate cortex (MCC)<sup>CaMKⅡ</sup> pathways are enhanced in the pain-anxiety comorbidity. The ventral hippocampal CA1 (vCA1)→BLA and BLA→CeA pathways were decreased in the pain-anxiety comorbidity. The BLA→ACC pathway was enhanced in the pain-depression comorbidity. The infralimbic cortex (IL)→locus coeruleus (LC) pathway was enhanced whereas the vCA1→IL pathway was decreased, in the pain-cognition comorbidity. Inflammation/neuroinflammation, oxidative stress, apoptosis, ferroptosis, gut-brain axis dysfunction, and gut microbiota dysbiosis also contribute to these comorbidities.</div></div>","PeriodicalId":13195,"journal":{"name":"IBRO Neuroscience Reports","volume":"18 ","pages":"Pages 414-431"},"PeriodicalIF":2.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143578874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in the molecular mechanisms of zinc-finger transcription factors in neurodevelopmental disorders

IF 2 Q3 NEUROSCIENCES

IBRO Neuroscience Reports

Pub Date : 2025-02-26 DOI: 10.1016/j.ibneur.2025.02.010

Hailin Wang , Ying Yang , Ziwei Ni , Xiaoting Qiao , Yaqian Guo , Xiaomin Wang , Duo Cao , Yayun Wang , Cailian Ruan

Neurodevelopmental disorders (NDDs) constitute a heterogeneous group of early-onset brain dysfunction disorders, which may arise from genetic or acquired etiologies. These disorders are characterized by behavioral and cognitive deficits that predominantly manifest during childhood development, thereby potentially impairing an individual's performance in learning, sports, and social situations. A comprehensive understanding of the pathogenesis of NDDs is crucial for the development of targeted therapeutic interventions. Zinc-finger transcription factors (ZFPs) play a pivotal role in regulating gene expression by modulating the binding of RNA polymerase to DNA, thereby either activating or repressing gene transcription. In recent years, the BCL11 gene family of ZFPs has garnered significant attention due to its critical involvement in nervous system development. This review aims to elucidate the structure and molecular functions of the BCL11 gene family, discuss its impact on the development of the central nervous system, and explore its association with neurodevelopmental disorders.

{"title":"Advances in the molecular mechanisms of zinc-finger transcription factors in neurodevelopmental disorders","authors":"Hailin Wang , Ying Yang , Ziwei Ni , Xiaoting Qiao , Yaqian Guo , Xiaomin Wang , Duo Cao , Yayun Wang , Cailian Ruan","doi":"10.1016/j.ibneur.2025.02.010","DOIUrl":"10.1016/j.ibneur.2025.02.010","url":null,"abstract":"<div><div>Neurodevelopmental disorders (NDDs) constitute a heterogeneous group of early-onset brain dysfunction disorders, which may arise from genetic or acquired etiologies. These disorders are characterized by behavioral and cognitive deficits that predominantly manifest during childhood development, thereby potentially impairing an individual's performance in learning, sports, and social situations. A comprehensive understanding of the pathogenesis of NDDs is crucial for the development of targeted therapeutic interventions. Zinc-finger transcription factors (ZFPs) play a pivotal role in regulating gene expression by modulating the binding of RNA polymerase to DNA, thereby either activating or repressing gene transcription. In recent years, the <em>BCL11</em> gene family of ZFPs has garnered significant attention due to its critical involvement in nervous system development. This review aims to elucidate the structure and molecular functions of the <em>BCL11</em> gene family, discuss its impact on the development of the central nervous system, and explore its association with neurodevelopmental disorders.</div></div>","PeriodicalId":13195,"journal":{"name":"IBRO Neuroscience Reports","volume":"18 ","pages":"Pages 409-413"},"PeriodicalIF":2.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phosphorylated alpha-synuclein distribution in the colonic enteric nervous system of patients with diverticular disease

IF 2 Q3 NEUROSCIENCES

IBRO Neuroscience Reports

Pub Date : 2025-02-26 DOI: 10.1016/j.ibneur.2025.02.009

François Cossais , Marie Christin Hörnke , Katja Schröder , Ralph Lucius , Martina Böttner , Jan-Hendrik Egberts , Florian Richter , Thilo Wedel

Background

Phosphorylated alpha-synuclein (P-aSyn) is a biomarker for Parkinson’s disease (PD), with potential relevance in intestinal inflammatory disorders.

Objectives

This study examines the distribution of P-aSyn in colonic tissues of patients with diverticular disease (DD) compared to age-matched controls.

Methods

P-aSyn distribution was analyzed in colon samples of 45 patients with diverticulitis (D-itis), 12 with diverticulosis (D-osis), and 30 controls via immunohistochemistry.

Results

P-aSyn immunoreactivity was found along enteric neurons of the myenteric and submucosal plexus in 93.1 % of participants, with similar distribution across D-itis, D-osis, and controls. Elevated reactivity appeared in 16.7 % of D-osis, 19.6 % of D-itis, and 30.0 % of controls.

Conclusion

P-aSyn presence in colonic tissue did not significantly differ between DD patients and controls, suggesting that DD-related inflammation does not notably affect P-aSyn expression. Further research is warranted to explore aSyn roles within the enteric nervous system in intestinal inflammatory disorders and their relation with neurodegenerative diseases.

{"title":"Phosphorylated alpha-synuclein distribution in the colonic enteric nervous system of patients with diverticular disease","authors":"François Cossais , Marie Christin Hörnke , Katja Schröder , Ralph Lucius , Martina Böttner , Jan-Hendrik Egberts , Florian Richter , Thilo Wedel","doi":"10.1016/j.ibneur.2025.02.009","DOIUrl":"10.1016/j.ibneur.2025.02.009","url":null,"abstract":"<div><h3>Background</h3><div>Phosphorylated alpha-synuclein (P-aSyn) is a biomarker for Parkinson’s disease (PD), with potential relevance in intestinal inflammatory disorders.</div></div><div><h3>Objectives</h3><div>This study examines the distribution of P-aSyn in colonic tissues of patients with diverticular disease (DD) compared to age-matched controls.</div></div><div><h3>Methods</h3><div>P-aSyn distribution was analyzed in colon samples of 45 patients with diverticulitis (D-itis), 12 with diverticulosis (D-osis), and 30 controls via immunohistochemistry.</div></div><div><h3>Results</h3><div>P-aSyn immunoreactivity was found along enteric neurons of the myenteric and submucosal plexus in 93.1 % of participants, with similar distribution across D-itis, D-osis, and controls. Elevated reactivity appeared in 16.7 % of D-osis, 19.6 % of D-itis, and 30.0 % of controls.</div></div><div><h3>Conclusion</h3><div>P-aSyn presence in colonic tissue did not significantly differ between DD patients and controls, suggesting that DD-related inflammation does not notably affect P-aSyn expression. Further research is warranted to explore aSyn roles within the enteric nervous system in intestinal inflammatory disorders and their relation with neurodegenerative diseases.</div></div>","PeriodicalId":13195,"journal":{"name":"IBRO Neuroscience Reports","volume":"18 ","pages":"Pages 384-388"},"PeriodicalIF":2.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143550150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acupuncture protects against ischemic stroke by inhibiting the NF-κB pathway

IF 2 Q3 NEUROSCIENCES

IBRO Neuroscience Reports

Pub Date : 2025-02-26 DOI: 10.1016/j.ibneur.2025.02.014

Linlin Wang , Lanrong Chen , Jiayong Wu , Chengyan Liu , Caixia Chi , Shicong Wang

Cerebral ischemia is a leading cause of disability and death worldwide. This study aims to investigate the neuroprotective effects of acupuncture on rats with middle cerebral artery occlusion (MCAO) and elucidate the underlying mechanisms involving the nuclear factor kappa-B (NF-κB) pathway and the NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome. Acupuncture at specific acupoints, i.e., GV26, GV20, and ST36, was administered to MCAO rats. Infarct volume was measured by TTC (2,3,5-triphenyl-tetrazolium chloride solution) staining. Protein expression levels of NF-κB pathway components and inflammatory markers were determined by western blot and enzyme-linked immunosorbent assay. Terminal deoxynucleotidyl transferase dUTP nick end labeling and hematoxylin-eosin staining were performed to evaluate apoptosis and histopathologic changes. Acupuncture significantly improved neurological function and reduced infarct volume in MCAO rats, as evidenced by decreased TTC staining areas. Meanwhile, acupuncture reduced NF-κB pathway, NLRP3 inflammasome and pro-inflammatory cytokines. Compared with the MCAO group, apoptotic cells were significantly reduced in the acupuncture group, which attenuated the histopathological changes induced by cerebral ischemia, including neuronal cell damage and tissue disorganization. However, application of phorbol 12-myristate 13-acetate partially reversed the beneficial effects of acupuncture, suggesting that the NF-κB pathway plays a key role in mediating the neuroprotective effects of acupuncture. Acupuncture exerts significant neuroprotective effects in MCAO rats, possibly through inhibition of the NF-κB pathway and NLRP3 inflammasome activation. These findings provide insight into the mechanisms of acupuncture in the treatment of ischemic stroke and support its potential therapeutic application.

{"title":"Acupuncture protects against ischemic stroke by inhibiting the NF-κB pathway","authors":"Linlin Wang , Lanrong Chen , Jiayong Wu , Chengyan Liu , Caixia Chi , Shicong Wang","doi":"10.1016/j.ibneur.2025.02.014","DOIUrl":"10.1016/j.ibneur.2025.02.014","url":null,"abstract":"<div><div>Cerebral ischemia is a leading cause of disability and death worldwide. This study aims to investigate the neuroprotective effects of acupuncture on rats with middle cerebral artery occlusion (MCAO) and elucidate the underlying mechanisms involving the nuclear factor kappa-B (NF-κB) pathway and the NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome. Acupuncture at specific acupoints, i.e., GV26, GV20, and ST36, was administered to MCAO rats. Infarct volume was measured by TTC (2,3,5-triphenyl-tetrazolium chloride solution) staining. Protein expression levels of NF-κB pathway components and inflammatory markers were determined by western blot and enzyme-linked immunosorbent assay. Terminal deoxynucleotidyl transferase dUTP nick end labeling and hematoxylin-eosin staining were performed to evaluate apoptosis and histopathologic changes. Acupuncture significantly improved neurological function and reduced infarct volume in MCAO rats, as evidenced by decreased TTC staining areas. Meanwhile, acupuncture reduced NF-κB pathway, NLRP3 inflammasome and pro-inflammatory cytokines. Compared with the MCAO group, apoptotic cells were significantly reduced in the acupuncture group, which attenuated the histopathological changes induced by cerebral ischemia, including neuronal cell damage and tissue disorganization. However, application of phorbol 12-myristate 13-acetate partially reversed the beneficial effects of acupuncture, suggesting that the NF-κB pathway plays a key role in mediating the neuroprotective effects of acupuncture. Acupuncture exerts significant neuroprotective effects in MCAO rats, possibly through inhibition of the NF-κB pathway and NLRP3 inflammasome activation. These findings provide insight into the mechanisms of acupuncture in the treatment of ischemic stroke and support its potential therapeutic application.</div></div>","PeriodicalId":13195,"journal":{"name":"IBRO Neuroscience Reports","volume":"18 ","pages":"Pages 370-377"},"PeriodicalIF":2.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143512728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring synergistic effects: Atorvastatin and electrical stimulation in spinal cord injury therapy

IF 2 Q3 NEUROSCIENCES

IBRO Neuroscience Reports

Pub Date : 2025-02-25 DOI: 10.1016/j.ibneur.2025.02.012

Martina Magurova, Maria Bacova, Stefania Papcunova, Katarina Kiss Bimbova, Tomas Kuruc, Alexandra Kisucka, Lenka Ihnatova, Karolina Kucharova, Nadezda Lukacova, Jan Galik

Spinal cord trauma represents a significant clinical challenge, and improving patient outcomes is a main priority for many scientific teams globally. Despite advances in the understanding its pathogenesis, the overall mechanisms occurring in the spinal cord after traumatic injury remain unclear. This study explores the possible synergistic effects of a regenerative therapy that combines electrical stimulation with the anti-inflammatory drug Atorvastatin (ATR) after spinal cord injury (SCI). SCI was induced at the T9 segment under isoflurane anesthesia and applying a compression force of 40 g for 15 minutes. An oscillating field stimulator (OFS) was implanted subcutaneously, delivering a weak electric current (50 µA) that changed polarity every 15 minutes for six weeks to promote axonal growth at the injury site. Female Wistar albino rats were divided into four groups: SCI with non-functional stimulator (SCI + nOFS), SCI with functional stimulator (SCI+OFS), and two groups that received ATR together with stimulator for 7 days after injury (SCI+OFS+ATR, SCI+nOFS+ATR). Behavioral tests (hot-plate test and BBB scale) showed improvement in sensory and motor performance in animals treated with the combination therapy. The protein levels of astrocytes (GFAP), neurofilaments (NF-L), newly sprouting axons (GAP-43), and oligodendrocytes (PLP −1, CNPase) were analysed by Western blot. The results showed increased neurofilaments, newly sprouting axons and oligodendrocytes in groups receiving both individual and combination therapies, with a decrease in their concentrations in the following order: SCI+OFS+ATR, SCI+nOFS+ATR, SCI+OFS, SCI+nOFS. In addition, astrocyte protein levels were lower in the SCI+OFS+ATR group compared with others. Histological analysis showed a significant reduction in white and gray matter after SCI, but less white and gray matter volume loss was found in the groups receiving therapies (SCI+OFS+ATR, SCI+nOFS+ATR, SCI+OFS). These results suggest that the combination of Atorvastatin with OFS stimulation promotes neural recovery after SCI, highlighting the potential of combination therapies in enhancing regenerative outcomes.

{"title":"Exploring synergistic effects: Atorvastatin and electrical stimulation in spinal cord injury therapy","authors":"Martina Magurova, Maria Bacova, Stefania Papcunova, Katarina Kiss Bimbova, Tomas Kuruc, Alexandra Kisucka, Lenka Ihnatova, Karolina Kucharova, Nadezda Lukacova, Jan Galik","doi":"10.1016/j.ibneur.2025.02.012","DOIUrl":"10.1016/j.ibneur.2025.02.012","url":null,"abstract":"<div><div>Spinal cord trauma represents a significant clinical challenge, and improving patient outcomes is a main priority for many scientific teams globally. Despite advances in the understanding its pathogenesis, the overall mechanisms occurring in the spinal cord after traumatic injury remain unclear. This study explores the possible synergistic effects of a regenerative therapy that combines electrical stimulation with the anti-inflammatory drug Atorvastatin (ATR) after spinal cord injury (SCI). SCI was induced at the T9 segment under isoflurane anesthesia and applying a compression force of 40 g for 15 minutes. An oscillating field stimulator (OFS) was implanted subcutaneously, delivering a weak electric current (50 µA) that changed polarity every 15 minutes for six weeks to promote axonal growth at the injury site. Female Wistar albino rats were divided into four groups: SCI with non-functional stimulator (SCI + nOFS), SCI with functional stimulator (SCI+OFS), and two groups that received ATR together with stimulator for 7 days after injury (SCI+OFS+ATR, SCI+nOFS+ATR). Behavioral tests (hot-plate test and BBB scale) showed improvement in sensory and motor performance in animals treated with the combination therapy. The protein levels of astrocytes (GFAP), neurofilaments (NF-L), newly sprouting axons (GAP-43), and oligodendrocytes (PLP −1, CNPase) were analysed by Western blot. The results showed increased neurofilaments, newly sprouting axons and oligodendrocytes in groups receiving both individual and combination therapies, with a decrease in their concentrations in the following order: SCI+OFS+ATR, SCI+nOFS+ATR, SCI+OFS, SCI+nOFS. In addition, astrocyte protein levels were lower in the SCI+OFS+ATR group compared with others. Histological analysis showed a significant reduction in white and gray matter after SCI, but less white and gray matter volume loss was found in the groups receiving therapies (SCI+OFS+ATR, SCI+nOFS+ATR, SCI+OFS). These results suggest that the combination of Atorvastatin with OFS stimulation promotes neural recovery after SCI, highlighting the potential of combination therapies in enhancing regenerative outcomes.</div></div>","PeriodicalId":13195,"journal":{"name":"IBRO Neuroscience Reports","volume":"18 ","pages":"Pages 389-399"},"PeriodicalIF":2.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143550151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A dual-genotype IDH-mutant infiltrating glioma, a real oligoastrocytoma in cerebral hemisphere

IF 2 Q3 NEUROSCIENCES

IBRO Neuroscience Reports

Pub Date : 2025-02-25 DOI: 10.1016/j.ibneur.2025.02.013

Jing Liu PhD , Fan Lin PhD , Yanhua Sun MM , Xia Liu MM

Since the 5th edition of CNS WHO classification. the categorization of oligoastrocytoma has been discontinued. It is now understood that the majority of tumors previously identified as oligoastrocytomas can be reclassified into either astrocytomas or oligodendrogliomas based on molecular characteristics. In this report, we present a rare case of true oligoastrocytoma characterized by the coexistence of two distinct cell types within a single tumor mass, as evidenced in imaging findings and histological examination. The left frontal infiltrating glioma displayed calcification, and histological analysis revealed two morphologically distinct regions corresponding to oligodendroglioma and astrocytoma. Immunohistochemical and molecular pathology analyses, including IDH1, ATRX, TP53 mutations, H3K27me3 status, Tert promoter mutations, and 1p/19q co-deletion, are consistent with oligodendroglioma and astrocytoma, respectively. Post-surgery, the patient opted against radiotherapy and chemotherapy and showed no signs of recurrence at a 4-month follow-up, but was subsequently lost to follow-up. This case prompts questions about the prognosis and potential grading criteria for true oligoastrocytoma. It underscores the need for further case studies to potentially re-establish it as a distinct tumor type in future CNS WHO classifications.

{"title":"A dual-genotype IDH-mutant infiltrating glioma, a real oligoastrocytoma in cerebral hemisphere","authors":"Jing Liu PhD , Fan Lin PhD , Yanhua Sun MM , Xia Liu MM","doi":"10.1016/j.ibneur.2025.02.013","DOIUrl":"10.1016/j.ibneur.2025.02.013","url":null,"abstract":"<div><div>Since the 5th edition of CNS WHO classification. the categorization of oligoastrocytoma has been discontinued. It is now understood that the majority of tumors previously identified as oligoastrocytomas can be reclassified into either astrocytomas or oligodendrogliomas based on molecular characteristics. In this report, we present a rare case of true oligoastrocytoma characterized by the coexistence of two distinct cell types within a single tumor mass, as evidenced in imaging findings and histological examination. The left frontal infiltrating glioma displayed calcification, and histological analysis revealed two morphologically distinct regions corresponding to oligodendroglioma and astrocytoma. Immunohistochemical and molecular pathology analyses, including IDH1, ATRX, TP53 mutations, H3K27me3 status, Tert promoter mutations, and 1p/19q co-deletion, are consistent with oligodendroglioma and astrocytoma, respectively. Post-surgery, the patient opted against radiotherapy and chemotherapy and showed no signs of recurrence at a 4-month follow-up, but was subsequently lost to follow-up. This case prompts questions about the prognosis and potential grading criteria for true oligoastrocytoma. It underscores the need for further case studies to potentially re-establish it as a distinct tumor type in future CNS WHO classifications.</div></div>","PeriodicalId":13195,"journal":{"name":"IBRO Neuroscience Reports","volume":"18 ","pages":"Pages 366-369"},"PeriodicalIF":2.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetic variants of ZNF746 and the level of plasma Parkin, PINK1, and ZNF746 proteins in patients with Parkinson's disease

IF 2 Q3 NEUROSCIENCES

IBRO Neuroscience Reports

Pub Date : 2025-02-15 DOI: 10.1016/j.ibneur.2025.01.016

Jolanta Dorszewska , Jolanta Florczak-Wyspiańska , Bartosz Słowikowski , Wojciech Owecki , Oliwia Szymanowicz , Ulyana Goutor , Mateusz Dezor , Paweł P. Jagodziński , Wojciech Kozubski

The occurrence of Parkinson's disease (PD) is influenced by a combination of genetic and environmental factors. Genetic variants of PARK2 (PRKN), PARK6 (PINK1), ZNF746, and their protein products are considered parameters related to the occurrence and development of PD. There is an interplay between Parkin, PINK1, and ZNF746 proteins. Inactivation of Parkin or PINK1 proteins results in elevated levels of the neurotoxic ZNF746 protein and loss of dopaminergic neurons. The objective of this study was to investigate the genetic variations in ZNF746 and the levels of Parkin, PINK1, and ZNF746 proteins in both PD patients and controls within the Polish population. The study included 125 controls and 100 PD patients. Genetic variants were analyzed using PCR-HRM and sequencing. The concentration of Parkin, PINK1, and ZNF746 proteins in plasma was determined by ELISA. The presence of three new genetic variants of ZNF746, chr7:149492883 G>A, ch7:149492890 G>A, ch7:149492694 G>A was demonstrated and the occurrence of ZNF746 c.473 G>A and ch7:149492754 A>G (rs191173107) was confirmed in Polish subjects. There was a significant decrease in Parkin concentration (p < 0.05) observed in PD patients when compared to controls. Reduced levels of Parkin were correlated with a significant rise in the concentration of ZNF746 (p < 0.05) in PD patients when compared with controls. PINK1 protein exhibited no notable alterations in concentration, except in patients who carried the heterozygous ZNF746 variant at ch7:149492694 G>A. The study of ZNF746 variants combined with the assessment of levels of Parkin, PINK1, and ZNF746 proteins provides fresh insights into our understanding of PD pathogenesis.

{"title":"Genetic variants of ZNF746 and the level of plasma Parkin, PINK1, and ZNF746 proteins in patients with Parkinson's disease","authors":"Jolanta Dorszewska , Jolanta Florczak-Wyspiańska , Bartosz Słowikowski , Wojciech Owecki , Oliwia Szymanowicz , Ulyana Goutor , Mateusz Dezor , Paweł P. Jagodziński , Wojciech Kozubski","doi":"10.1016/j.ibneur.2025.01.016","DOIUrl":"10.1016/j.ibneur.2025.01.016","url":null,"abstract":"<div><div>The occurrence of Parkinson's disease (PD) is influenced by a combination of genetic and environmental factors. Genetic variants of PARK2 (<em>PRKN</em>), PARK6 (<em>PINK1</em>), <em>ZNF746,</em> and their protein products are considered parameters related to the occurrence and development of PD. There is an interplay between Parkin, PINK1, and ZNF746 proteins. Inactivation of Parkin or PINK1 proteins results in elevated levels of the neurotoxic ZNF746 protein and loss of dopaminergic neurons. The objective of this study was to investigate the genetic variations in <em>ZNF746</em> and the levels of Parkin, PINK1, and ZNF746 proteins in both PD patients and controls within the Polish population. The study included 125 controls and 100 PD patients. Genetic variants were analyzed using PCR-HRM and sequencing. The concentration of Parkin, PINK1, and ZNF746 proteins in plasma was determined by ELISA. The presence of three new genetic variants of <em>ZNF746</em>, chr7:149492883 G>A, ch7:149492890 G>A, ch7:149492694 G>A was demonstrated and the occurrence of <em>ZNF746</em> c.473 G>A and ch7:149492754 A>G (rs191173107) was confirmed in Polish subjects. There was a significant decrease in Parkin concentration (p < 0.05) observed in PD patients when compared to controls. Reduced levels of Parkin were correlated with a significant rise in the concentration of ZNF746 (p < 0.05) in PD patients when compared with controls. PINK1 protein exhibited no notable alterations in concentration, except in patients who carried the heterozygous <em>ZNF746</em> variant at ch7:149492694 G>A. The study of <em>ZNF746</em> variants combined with the assessment of levels of Parkin, PINK1, and ZNF746 proteins provides fresh insights into our understanding of PD pathogenesis.</div></div>","PeriodicalId":13195,"journal":{"name":"IBRO Neuroscience Reports","volume":"18 ","pages":"Pages 342-349"},"PeriodicalIF":2.0,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143436465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Regulation of non-emotional memory through α1-adrenergic receptors activation: A short review

IF 2 Q3 NEUROSCIENCES

IBRO Neuroscience Reports

Pub Date : 2025-02-14 DOI: 10.1016/j.ibneur.2025.02.005

Eugénia Correia de Barros

The α₁ adrenergic receptors (α₁-ARs) play a central role in the regulation of synaptic plasticity and memory, but their role in non-emotional memory is still poorly understood. This review summarizes recent advances in understanding the functions of α₁-ARs and highlights their contributions to synaptic efficacy, long-term potentiation (LTP), and long-term depression (LTD) in the hippocampus and neocortex. There is evidence that α₁-AR activation occurs through intracellular pathways such as Gq-protein signaling, MAPK, and cAMP cascades. Furthermore, α₁-ARs are emerging as promising therapeutic targets in neurodegenerative diseases, including Alzheimer’s disease (AD), due to their capability to modulate cognition and neuronal plasticity. New insights into positive allosteric modulators (PAMs) that cross the blood-brain barrier provide a potential avenue for safer and more effective therapies. This review highlights the need for further research to improve the understanding of α₁-ARs and their potential for memory enhancement and neuroprotection.

引用次数: 0